

# Extracellular Mitochondrial ATP, Suramin, and Autism?

Theoharis C. Theoharides, MS, MPhil, PhD, MD<sup>1,2,3</sup>

<sup>1</sup>*Molecular Immunopharmacology and Drug Discovery Laboratory, Integrative Physiology and Pathobiology;*  
<sup>2</sup>*Departments of Biochemistry, Internal Medicine, and Psychiatry, Tufts University School of Medicine and Tufts Medical Center, Boston, MA; and* <sup>3</sup>*Theta Biomedical Consulting and Development Co, Inc, Brookline, MA*

A recent publication reported that pregnant mice injected with the viral-like material Poly(I:C) produced, as previously known, offspring that exhibit behavior reminiscent of autism; it also reported that therapy with the antipurinergic drug suramin, used to treat the African disease trypanosomiasis, blocked ATP (a purine)-dependent biochemical and behavioral changes in these mice.<sup>1</sup> The authors asserted that this represents a new theory of mitochondrial-derived purinergic chemicals leaking outside a cell and signaling danger to surrounding cells.<sup>1</sup> This is an exciting finding and may suggest an important role of extracellular ATP in autism. However, this theory is apparently contrary to numerous reports of dysfunctional mitochondria and reduced ATP in patients with autism.<sup>2,3</sup>

The release of mitochondrial molecules extracellularly is not new. Extracellular ATP was previously considered a universal alarm signal released from cells under stress and capable of affecting neighboring cells,<sup>4</sup> including mast cells.<sup>5</sup> Extracellular ATP was also reported to augment inflammatory brain disease,<sup>6</sup> microglial survival,<sup>7</sup> as well as trigger and maintain inflammation in asthmatic airways.<sup>8</sup>

Nevertheless the findings by Naviaux et al,<sup>9</sup> are supported by previous studies showing that extracellular mitochondrial material could be released from activated mast cells, unique immune cells involved in allergies and eczema.<sup>10</sup> Many patients with autism have food allergies<sup>11</sup> and allergic-like symptoms<sup>12,13</sup> suggesting mast cell activation.<sup>14,15</sup> A recent epidemiologic study of 92,642 children reported a strong correlation between atopic dermatitis (ie, eczema), attention deficit hyperactivity disorder, and autism.<sup>16</sup> Moreover, children with mastocytosis, a spectrum of diseases that present with skin allergies,

hyperactivity, and difficulty focusing,<sup>17</sup> appear to have a 5-fold higher prevalence of autism spectrum disorder (1 out of 10 children) than that reported for the general population.<sup>18</sup>

This extracellular mitochondrial material could induce an intense autoimmune reaction from other cells,<sup>19,20</sup> including augmentation of allergic responses,<sup>21</sup> and could lead to focal brain inflammation.<sup>22</sup> About 50% of this material contained ATP, the action of which could be blocked by purinergic receptor inhibitors. The clinical importance of these findings was the fact that DNA was elevated in young children with autism.<sup>23</sup> All findings in the study using suramin were based on the assumption that it is a specific antipurinergic drug.<sup>1</sup> However, suramin is nonspecific and can affect G-coupled receptors,<sup>24</sup> as well as inhibit mast cells secretion,<sup>5</sup> T cell proliferation,<sup>25</sup> and polymorphonuclear leukocyte bactericidal activity.<sup>26</sup>

The authors did not explain how an antipurinergic effect could prevent the behavioral changes in the poly (I:C) mouse model that had been shown to depend on interleukin (IL)-6 increase<sup>27</sup> and not to develop in IL-6 null mice,<sup>28</sup> unless suramin blocks the release or antagonizes the action of IL-6. One possibility might be that activation of purinergic receptors leads to IL-6 release that could be indirectly blocked by suramin as it is blocked by luteolin in microglia.<sup>29,30</sup> In fact, suranim can also block G-coupled receptors, ATPases,<sup>31</sup> and mast cells.<sup>32,33</sup> Given the fact that poly (I:C) maternal infection model does not occur in IL-6 knockout mice,<sup>28,34</sup> and that most of the IL-6 depends on mast cells,<sup>35</sup> one wonders if the actions of suramin

Accepted for publication July 12, 2013.

<http://dx.doi.org/10.1016/j.clinthera.2013.07.419>  
0149-2918/\$ - see front matter

© 2013 Elsevier HS Journals, Inc. All rights reserved.

reported are not due to antipurinergic actions as reported, but more due to effects on mast cells.<sup>22</sup>

The use of the term *therapy* in the title of the article<sup>1</sup> is unsuitable because we refer to therapy when the pathogenesis of a disease is known, unlike autism. This created unrealistic expectations from colleagues and patients. “Blocking purinergic receptors” or experimental “treatment” would have been more appropriate than “therapy” especially because mouse models poorly mimic inflammatory diseases in human beings.<sup>36</sup>

Suramin can induce severe urticarial reactions in more than 90% of patients and adrenal damage in about 50%; suramin can also impair renal function, induce blood dyscrasias, optic atrophy and peripheric neuritis.<sup>37</sup> It is also contraindicated in hepatic dysfunction.<sup>38</sup> Additional interactions with other drugs,<sup>39</sup> or with supplements commonly given to children with autism<sup>40</sup> may also occur.

#### ACKNOWLEDGMENTS

This work was funded in part by the Autism Research Institute, the National Autism Association, Safe Minds, and National Institutes of Health grant No. AR47652.

#### CONFLICTS OF INTEREST

Tufts University has filed on behalf of TCT the following US applications: No 61/405,414 (filed October 21, 2010) entitled “Extracellular mitochondria-based screening and treatment” and PCT/US11/57405 (filed October 21, 2011) entitled “Extracellular mitochondria-based screening and treatment”, as well as US 13/880,736 (filed October 21, 2013) entitled “Extracellular mitochondria-based screening and treatment.” The authors have indicated that they have no other conflicts of interest regarding the content of this article.

#### REFERENCES

1. Naviaux RK, Zolkipli Z, Wang L, et al. Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model. *PLoS One*. 2013;8:e57380.
2. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. *Mol Psychiatry*. 2012;17:290-314.
3. Giulivi C, Zhang YF, Omanska-Klusek A, et al. Mitochondrial dysfunction in autism. *JAMA*. 2010;304:2389-2396.
4. Corriden R, Insel PA. Basal release of ATP: an autocrine-paracrine mechanism for cell regulation. *Sci Signal*. 2010;3:re1.
5. Jaffar ZH, Pearce FL. Histamine secretion from mast cells stimulated with ATP. *Agents Actions*. 1990;30:64-66.
6. Chan A, Gold R, von AN. ATP-binding cassette transporters in inflammatory brain disease. *Curr Pharm Des*. 2011;17:2803-2807.
7. Harada K, Hide I, Seki T, et al. Extracellular ATP differentially modulates Toll-like receptor 4-mediated cell survival and death of microglia. *J Neurochem*. 2011;116:1138-1147.
8. Kouzaki H, Iijima K, Kobayashi T, et al. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. *J Immunol*. 2011;186:4375-4387.
9. Zhang B, Alysandratos KD, Angelidou A, et al. Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. *J Allergy Clin Immunol*. 2011;127:1522-1531.
10. Theoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. *Biochim Biophys Acta*. 2010;1822:21-33.
11. Jyonouchi H. Autism spectrum disorders and allergy: observation from a pediatric allergy/immunology clinic. *Expert Rev Clin Immunol*. 2010;6:397-411.
12. Theoharides TC. Is a subtype of autism “allergy of the brain”? *Clin Ther*. 2013;35:584-591.
13. Angelidou A, Alysandratos KD, Asadi S, et al. Brief Report: “Allergic Symptoms” in children with Autism Spectrum Disorders. More than meets the eye? *J Autism Dev Disord*. 2011;41:1579-1585.
14. Theoharides TC, Angelidou A, Alysandratos KD, et al. Mast cell activation and autism. *Biochim Biophys Acta*. 2012;1822:34-41.
15. Kempuraj D, Asadi S, Zhang B, et al. Mercury induces inflammatory mediator release from human mast cells. *J Neuroinflammation*. 2010;7:20.
16. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. *J Allergy Clin Immunol*. 2013;131:428-433.
17. Picard M, Giavina-Bianchi P, Mezzano V, et al. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. *Clin Ther*. 2013;35:548-562.
18. Theoharides TC. Autism spectrum disorders and mastocytosis. *Int J Immunopathol Pharmacol*. 2009;22:859-865.
19. Zhang B, Asadi S, Weng Z, et al. Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. *PLoS One*. 2012;7:e49767.

20. Theoharides TC. Extracellular mitochondrial components secreted from activated live mast cells act as “innate pathogens” and contribute to autism pathogenesis. *Intl Trends Immun.* 2013;1.
21. Asadi S, Theoharides TC. Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin. *J Neuroinflammation.* 2012; 9:85.
22. Theoharides TC, Asadi S, Patel A. Focal brain inflammation and autism. *J Neuroinflammation.* 2013;10: 46.
23. Zhang B, Angelidou A, Alysandratos KD, et al. Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. *J Neuroinflammation.* 2010;7:80.
24. Bolitho C, Bayl P, Hou JY, et al. The anti-apoptotic activity of albumin for endothelium is mediated by a partially cryptic protein domain and reduced by inhibitors of G-coupled protein and PI-3 kinase, but is independent of radical scavenging or bound lipid. *J Vasc Res.* 2007;44: 313–324.
25. Novales-Li P. Suramin exerts in vivo cytokine modulatory properties on splenocytes from experimental allergic encephalomyelitis-induced SJL mice: implications for autoimmune disease therapy. *Immunopharmacology.* 1996;35:155–162.
26. Roilides E, Paschalides P, Freifeld A, et al. Suppression of polymorphonuclear leukocyte bactericidal activity by suramin. *Antimicrob Agents Chemother.* 1993;37:495–500.
27. Hsiao EY, McBride SW, Chow J, et al. Modeling an autism risk factor in mice leads to permanent immune dysregulation. *Proc Natl Acad Sci U S A.* 2012;109:12776–12781.
28. Smith SE, Li J, Garbett K, et al. Maternal immune activation alters fetal brain development through interleukin-6. *J Neurosci.* 2007;27:10695–10702.
29. Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. *Proc Natl Acad Sci U S A.* 2008;105:7534–7539.
30. Meyer U, Feldon J, Dammann O. Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? *Pediatr Res.* 2011;69:26R–33R.
31. Chakravarty N. The role of plasma membrane  $Ca^{2+}Mg^{2+}$  activated adenosine triphosphate of rat mast cells on histamine release. *Acta Pharmacol Toxicol.* 1980;47:223–235.
32. Ganapaty S, Chandrashekhara VM, Narsu ML. Evaluation of anti-allergic activity of gossypin and suramin in mast cell-mediated allergy model. *Indian J Biochem Biophys.* 2010;47:90–95.
33. Nosal R, Pecivova J, Drabikova K. Evidence for intracellular histamine liberation in isolated rat mast cells. *Agents Actions.* 1982;12:601–617.
34. Hsiao EY, Patterson PH. Activation of the maternal immune system induces endocrine changes in the placenta via IL-6. *Brain Behav Immun.* 2011;25:604–615.
35. Huang M, Berry J, Kandere K, et al. Mast cell deficient W/W<sup>o</sup> mice lack stress-induced increase in serum IL-6 levels, as well as in peripheral CRH and vascular permeability, a model of rheumatoid arthritis. *Intl J Immunopathol Pharmacol.* 2002;15: 249–254.
36. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc Natl Acad Sci U S A.* 2013;110:3507–3512.
37. Kaur M, Reed E, Sartor O, et al. Suramin’s development: what did we learn? *Invest New Drugs.* 2002;20: 209–219.
38. Szende B, Lapis K, Jeney A, et al. Liver damaging effect of suramin in normal and carbon-tetrachloride treated rats. *Toxicol Pathol.* 1991;19: 266–272.
39. Ganesh VK, Muthuvel SK, Smith SA, et al. Structural basis for antagonism by suramin of heparin binding to vaccinia complement protein. *Biochemistry.* 2005;44:10757–10765.
40. Theoharides TC, Asadi S. Unwanted interactions among psychotropic drugs and other treatments for Autism Spectrum Disorders. *J Clin Psychopharmacol.* 2012;32:437–440.

---

**Address correspondence to:** Theoharis C. Theoharides, MS, MPhil, PhD, Department of Molecular Physiology and Pharmacology, Tufts University School of Medicine, 136 Harrison Ave, Boston, MA 02111. E-mail: theoharis.theoharides@tufts.edu